دورية أكاديمية
Adverse Events Following COVISHIELD Vaccination Among Adult Population in Bangladesh.
| العنوان: | Adverse Events Following COVISHIELD Vaccination Among Adult Population in Bangladesh. |
|---|---|
| المؤلفون: | Khalil MM; Sheikh Russel Gastroliver Institute and Hospital, Dhaka, Bangladesh., Mahbub-Uz-Zaman K; Sheikh Russel Gastroliver Institute and Hospital, Dhaka, Bangladesh., Hossain AS; American International University of Bangladesh, Dhaka, Bangladesh., Ahmed F; Sheikh Russel Gastroliver Institute and Hospital, Dhaka, Bangladesh., Chowdhury MFK; Sheikh Russel Gastroliver Institute and Hospital, Dhaka, Bangladesh., Khan ST; Sheikh Russel Gastroliver Institute and Hospital, Dhaka, Bangladesh., Miah MSA; Sheikh Russel Gastroliver Institute and Hospital, Dhaka, Bangladesh., Khaleque N; Sheikh Russel Gastroliver Institute and Hospital, Dhaka, Bangladesh., Kibria MG; Sheikh Russel Gastroliver Institute and Hospital, Dhaka, Bangladesh., Ahmed F; Sheikh Russel Gastroliver Institute and Hospital, Dhaka, Bangladesh., Khan AM; The University of Edinburgh, Edinburgh, UK. |
| المصدر: | SN comprehensive clinical medicine [SN Compr Clin Med] 2021; Vol. 3 (11), pp. 2207-2213. Date of Electronic Publication: 2021 Jul 31. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer International Publishing Country of Publication: Switzerland NLM ID: 101740833 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2523-8973 (Electronic) Linking ISSN: 25238973 NLM ISO Abbreviation: SN Compr Clin Med Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Switzerland : Springer International Publishing, [2019]- |
| مستخلص: | The study aimed to determine how frequently the adverse events of the COVISHIELD vaccine occur among the Bangladeshi population. This cross-sectional study was conducted at Sheikh Russel Gastroliver Institute and Hospital, Mohakhali, Dhaka, Bangladesh, in May 2021. The inclusion criteria were the adult populations who received the 2nd dose of the COVISHELD vaccine and had passed 28 days following the completion of the 2nd dose. Three hundred and five persons fulfilling the inclusion criteria were asked over the telephone-based on a predesigned questionnaire. The rates of adverse events were 54.1% and 41.3% after the 1st and 2nd dose of vaccine, respectively, and the difference was statistically significant ( p < 0.001). Pain at the injection site was the most common adverse event (32.5% following the 1st dose and 27.9% following the 2nd dose). All of the symptoms were mild and lasted for about 2 days. Age and comorbidities were significantly associated with the adverse events ( p < 0.001). Neither doses had any vaccine-related life-threatening adverse event nor had any symptoms related to vaccine-related blood clotting. Nineteen persons (6.2%) had been diagnosed with COVID-19 after the 1st dose of vaccination, and three (1%) persons had been diagnosed with COVID-19 after the 2nd dose of vaccination. As no significant life-threatening adverse event was observed, this study might help reduce the hesitancy for vaccination among the population and thus help reduce transmission of this highly contagious virus. Competing Interests: Competing InterestsThe authors declare no competing interests. (© The Author(s) 2021.) |
| References: | J Pain Symptom Manage. 2011 Jun;41(6):1073-93. (PMID: 21621130) Lancet. 2020 Aug 15;396(10249):467-478. (PMID: 32702298) Vaccines (Basel). 2021 Feb 03;9(2):. (PMID: 33546165) SN Compr Clin Med. 2020;2(10):1733-1739. (PMID: 32904377) ACS Cent Sci. 2021 Apr 28;7(4):594-602. (PMID: 34056089) Science. 2020 May 15;368(6492):779-782. (PMID: 32277040) Circulation. 2020 Sep 22;142(12):1176-1189. (PMID: 32755393) Clin Immunol. 2020 Jun;215:108427. (PMID: 32325252) Mymensingh Med J. 2020 Oct;29(4):956-963. (PMID: 33116102) Lancet. 2021 Dec 19;396(10267):1979-1993. (PMID: 33220855) J Hosp Med. 2012 Sep;7(7):567-72. (PMID: 22371388) J Clin Med. 2021 Apr 01;10(7):. (PMID: 33916020) Lancet. 2020 Feb 15;395(10223):507-513. (PMID: 32007143) |
| فهرسة مساهمة: | Keywords: Adverse Events; COVID 19; COVISHIELD; Oxford AstraZeneca; Vaccination |
| تواريخ الأحداث: | Date Created: 20210809 Latest Revision: 20240823 |
| رمز التحديث: | 20240823 |
| مُعرف محوري في PubMed: | PMC8324453 |
| DOI: | 10.1007/s42399-021-01021-z |
| PMID: | 34368624 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. | تدمد: | 2523-8973 |
|---|---|
| DOI: | 10.1007/s42399-021-01021-z |